Key takeaways
- DSIP is a small sleep-related peptide with early animal findings and a thin, mixed human record.
- MyPeps rates its evidence 2 out of 5, mostly small trials from the 1980s and 1990s.
- An advisory panel vote, yes or no, is a recommendation. It is not an approval and it is not a ban.
- Lack of FDA approval mostly reflects who paid for big trials, not proof that a compound fails.
DSIP, short for delta sleep-inducing peptide, was described to us as the one compound that lost a 6-7 vote at a July FDA advisory meeting, while six others got a yes. We could not confirm the details of that vote from the sources we are allowed to use for this post, so we won't describe the meeting, its reasoning or the other six compounds. What we can do is lay out what the research on DSIP actually says, which is a useful way to think about any vote.
Curiosity about DSIP is easy to understand. It is a tiny molecule with a memorable name and an interesting origin story. The evidence behind it is modest, and that is worth saying plainly and kindly.
What DSIP is and what the early work found
DSIP is a nonapeptide, meaning nine amino acids long. In early rabbit studies it induced delta-wave sleep, the slow, deep kind. Its mechanism is poorly understood, though it appears to modulate stress hormones and sleep architecture.
It also clears fast. The site entry gives a half-life of about 7–8 minutes, which makes it a puzzling candidate for something that is supposed to shape a whole night of sleep.
Human work exists, but it is small and inconsistent. The site entry lists possible benefits for sleep onset and for stress or withdrawal effects in people, based on mixed small trials from the 1980s and 1990s. There are no modern randomized controlled trials.
What newer papers add (and don't)
Recent literature is mostly preclinical. A 2024 mouse study used a chemically induced insomnia model and tested DSIP joined to a peptide meant to help cross the blood-brain barrier. According to the abstract, the fusion peptide changed levels of neurotransmitters including serotonin, glutamate, dopamine and melatonin, and did better than DSIP alone at restoring balance 1. That is an interesting engineering idea, but it is a mouse study, and the abstract is all we know of it here.
A January 2026 orthopaedic review lists DSIP among "recovery-enhancing" peptides that target circadian and mitochondrial regulators. The same abstract states that although preclinical studies are promising, there is a current lack of clinical trials 2. Again, we have only the abstract.
One more paper is worth a mention for a different reason. A 2023 chemistry study used DSIP as the showcase for a cleaner way to build peptides, with less chemical waste 3. It says nothing about whether DSIP works in people. It does show that researchers find the molecule a convenient, well-known test case.
Why a panel might hesitate
We can't speak for any panel. But here is what a reasonable reviewer would see in the record above:
- The human trials are decades old, small and mixed.
- The mechanism is poorly understood.
- The half-life is very short.
- The newest work is in mice or is a review noting the lack of clinical trials.
That is a thin file for a drug decision. It is not the same as a file showing the compound fails. "We don't have good evidence yet" and "this has been shown not to work" are different statements.
Why a vote is not an approval or a ban
An FDA advisory committee gives the agency advice. The agency decides, and a vote in either direction does not by itself approve or prohibit anything. A six-to-seven result is also close, which tells you opinions were divided rather than unanimous.
It also helps to know how approval usually works. Approval mostly tracks whether a company has paid for large, expensive trials, and many compounds never get that for money reasons. A peptide that is hard to patent has little commercial incentive behind it. So "not FDA-approved" is the ordinary situation for most of these compounds, and it does not tell you whether one works.
DSIP is also on the World Anti-Doping Agency's banned list, according to the site entry, which matters to competitive athletes.
What people's experience can and can't tell us
Some people use DSIP for sleep and stress and compare notes online. That is real experience, and it is a reasonable reason for researchers to look closer. It is not proof. Reports like these can't separate the peptide from placebo effects, changes in routine or ordinary night-to-night variation, and we won't put a number on how many people report anything.
If you are curious, a better question than "does it work?" may be "what trial would answer this?" A modern, placebo-controlled sleep study in people would settle much of the uncertainty. Nobody has funded one yet, as far as the sources here show.
The bottom line
DSIP is an intriguing sleep peptide with early rabbit and mouse findings, a small and mixed human record, and a MyPeps evidence rating of 2 out of 5. A panel vote, whichever way it goes, is advice and not a final ruling. The missing piece is not a verdict against DSIP but a modern human trial.
This is educational information, not medical advice.
Sources
- Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models — Frontiers in pharmacology, Oct 2024. https://pubmed.ncbi.nlm.nih.gov/39444618/
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, Jan 2026. https://pubmed.ncbi.nlm.nih.gov/41490200/
- Practical N-to-C peptide synthesis with minimal protecting groups — Communications chemistry, Oct 2023. https://pubmed.ncbi.nlm.nih.gov/37884638/